Stroke · patients with heart failure
Coenzyme Q10 showed no clear difference in stroke compared with placebo or conventional therapy (low certainty).
1 finding from 1 review
Heart failure hospitalisation (RR) · patients with heart failure
Coenzyme Q10 probably leads to lower hospitalisation for heart failure compared with placebo or conventional therapy (moderate certainty).
1 finding from 1 review
Left ventricular ejection fraction (%) · patients with heart failure
1 finding from 1 review
Exercise capacity · patients with heart failure
1 finding from 1 review
Adverse events · patients with heart failure
Coenzyme Q10 showed no clear difference in adverse events compared with placebo or conventional therapy (low certainty).
1 finding from 1 review
Change in symptoms (ranging from 1 week to 3 months) · people with varicose veins without venous ulceration
1 finding from 1 review
Measures of physiological function · people with varicose veins without venous ulceration
1 finding from 1 review
Complications (1 week, 4 weeks and up to 6 weeks' postpartumc) · people with varicose veins without venous ulceration
1 finding from 1 review
Compliance · people with varicose veins without venous ulceration
1 finding from 1 review
Comfort, tolerance and acceptability of wearing stockings (1 week and up to 6 weeks' postpartumc) · people with varicose veins without venous ulceration
1 finding from 1 review
Quality of life (3 months) · people with varicose veins without venous ulceration
1 finding from 1 review
50% or greater reduction in seizure frequency · adults and children with drug‐resistant focal epilepsy
Any dose of lacosamide leads to higher 50% or greater reduction in seizure frequency compared with placebo (high certainty).
1 finding from 1 review
Seizure freedom · adults and children with drug‐resistant focal epilepsy
Any dose of lacosamide may leads to higher seizure freedom compared with placebo (low certainty).
1 finding from 1 review
Treatment withdrawal · adults and children with drug‐resistant focal epilepsy
Any dose of lacosamide probably leads to higher treatment withdrawal compared with placebo (moderate certainty).
1 finding from 1 review
Dizziness · adults and children with drug‐resistant focal epilepsy
Any dose of lacosamide leads to higher dizziness compared with placebo (high certainty).
1 finding from 1 review
Headache · adults and children with drug‐resistant focal epilepsy
Any dose of lacosamide probably leads to higher headache compared with placebo (moderate certainty).
1 finding from 1 review
Vomiting · adults and children with drug‐resistant focal epilepsy
Any dose of lacosamide probably leads to higher vomiting compared with placebo (moderate certainty).
1 finding from 1 review
Serious adverse events · adults and children with drug‐resistant focal epilepsy
Any dose of lacosamide probably leads to higher serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
FEV1 % predicted: absolute change from baseline · children and young adults with CF
1 finding from 1 review
FEV1 % predicted: absolute change from baseline · children and young adults with CF
1 finding from 1 review